Neoleukin Therapeutics, Inc. (NLTX) 是一家上市公司 属于 医疗保健 板块，经营于 制药 - 专科与仿制药 行业. 公司总部位于 Seattle, WA, 美国. 现任CEO为 Donna M. Cochener-Metcalfe.
NLTX 拥有 IPO日期为 2014-03-07, 7 名全职员工, 在 NASDAQ Global Market, 市值为 $8.2M.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
